Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs SNN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

SNN Overall Winner 6-Pillar Tally: RBOT.WS 0 – 5 SNN (1 Tie) Matrix Metrics: RBOT.WS 1 – 9 SNN

As of Nov 20, 2026, Smith & Nephew plc (SNN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas SNN carries 36.9/100 (SELL) at $29.83 (12.6x Forward P/E, 14.2% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. SNN 36.9/100 SELL), SNN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.2% vs. N/A operating margin) and revenue trajectory (+4.6% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs SNN
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
SNN NYSE Head-to-Head Winner
Smith & Nephew plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.83
+0.0% 1D
Market Cap $12.5B
TTM Revenue $6.30B
Forward P/E 12.6x
Beta / 30D Vol 0.27β · 32% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 39.0 Fund 36.0 Flow 50.0 Mom 16.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.5 · SMA20: $30.68 · SMA50: $28.97

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 5 SNN)

Columns: Metric · RBOT.WS · SNN
1. Valuation Multiples SNN
Forward P/E N/M 12.6x
Trailing P/E N/M 20.3x
PEG Ratio N/M 1.11x
EV / Revenue N/M 2.0x
2. Growth & Scale SNN
Revenue Growth (YoY) N/A +4.6%
Earnings Growth (YoY) N/A +5.7%
TTM Revenue (USD) N/A $6.30B
Market Cap N/A $12.5B
3. Profitability & Quality SNN
Gross Margin N/A 68.4%
Operating Margin N/A 14.2%
Net Profit Margin N/A 10.1%
Return on Equity (ROE) N/A 11.8%
4. Balance Sheet & Cash Flow SNN
Cash Generation (TTM) N/A $1.38B EBITDA
Cash Flow Margin N/A 21.9% EBITDA Mgn
Net Cash / Leverage N/A ROE $2.43 Book/Sh · 11.8% ROE
Dividend Yield None (0.00%) 2.66%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 19.6% (50th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNN
OpEx & R&D Intensity N/A 54.2% of Rev ($3.41B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs SNN (9)
Institutional Metric RBOT.WS SNN Criterion Row Edge
Market Capitalization
Scale
N/A $12.5B Larger Scale SNN
Trailing P/E Ratio
Valuation
N/M 20.3x Lower Multiple SNN
Forward P/E Ratio
Valuation
N/M 12.6x Lower Multiple SNN
Revenue Growth (YoY)
Growth
N/A +4.6% Higher Growth SNN
Operating Margin (TTM)
Profitability
N/A 14.2% Higher Margin SNN
Net Profit Margin
Profitability
N/A 10.1% Higher Margin SNN
Return on Equity (ROE)
Capital Efficiency
N/A 11.8% Higher ROE SNN
52-Week Range Position
Momentum
0% ($0–$0) 34% ($26–$37) Stronger Trend SNN
Beta / 30D Volatility
Risk Regime
N/A 0.27β · 32% Vol Lower Realized Risk SNN
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 36.9 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $6.30B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 68.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.11x PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $1.38B EBITDA ($2.43 Book/Sh · 11.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNN +68.26 pp
RBOT.WS: -67.2% · SNN: +1.06%
3M Horizon SNN +68.26 pp
RBOT.WS: -67.2% · SNN: +1.06%
6M Horizon SNN +68.26 pp
RBOT.WS: -67.2% · SNN: +1.06%
1Y Horizon SNN +68.26 pp
RBOT.WS: -67.2% · SNN: +1.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs SNN. Trailing 12-month operating profitability (RBOT.WS N/A vs SNN 14.2%) and valuation multiples (RBOT.WS N/M vs SNN 12.6x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SNN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.30B
Gross Margin68.4%
Op. Margin14.2%
ROE / Fwd P/E11.8% · 12.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 19.6%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SNN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.5B market capitalization and 14.2% operating margin.
OpEx & R&D Reinvestment 54.2% of Rev ($3.41B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs SNN Key Questions & Quantitative Answers

As of Nov 20, 2026, Smith & Nephew plc (SNN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas SNN carries 36.9/100 (SELL) at $29.83 (12.6x Forward P/E, 14.2% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. SNN 36.9/100 SELL), SNN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.2% vs. N/A operating margin) and revenue trajectory (+4.6% vs. N/A YoY).

SNN leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SNN at +4.6% YoY revenue growth and +5.7% YoY earnings growth on $6.30B TTM revenue (68.4% gross margin, 14.2% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $6.30B for SNN. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 54.2% of Rev ($3.41B) (0 disclosures) for SNN.

SNN screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SNN trades at 12.6x Forward P/E, 20.3x Trailing P/E, 1.11x PEG, and 2.0x EV/Revenue (21.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus SNN (11.8% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, SNN carries 19.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.